"シオノギ" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonNotice of Head Office Relocation｜ 塩野義製薬 - Shionogi
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - GlobeNewswire
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia GlobeNewswire
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Reuters.com
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission Reuters.com
Shionogi's Strategies for Addressing Antibiotic Efficacy and Resistance - Contagionlive.com
Shionogi's Strategies for Addressing Antibiotic Efficacy and Resistance Contagionlive.com
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement f...
Nxera and Shionogi launch Quviviq in Japan - The Pharma Letter
Nxera and Shionogi launch Quviviq in Japan The Pharma Letter
Antibiotics, an important but tricky business, says Shionogi CEO - EURACTIV
Antibiotics, an important but tricky business, says Shionogi CEO EURACTIV
David Benadon｜ 塩野義製薬 - Shionogi
David Benadon｜ 塩野義製薬 Shionogi
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan - GlobeNewswire
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan GlobeNewswire
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentation...
Shionogi to acquire full ownership of joint ventures with Ping An - The Pharma Letter
Shionogi to acquire full ownership of joint ventures with Ping An The Pharma Letter
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...
Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Includi...
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 - Shionogi
Significance of SHIONOGI’s Challenge in the “Resource Recycle Project”｜ 塩野義製薬 Shionogi
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for...
Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library ...
SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...
“Pharmaceutical Education” by Virtual Employee｜ SHIONOGI - Shionogi
“Pharmaceutical Education” by Virtual Employee｜ SHIONOGI Shionogi
Striving for Palliative Care that Leaves No One Behind: Aiming for a Communication Barrier-Free R...
Leveraging Real-world Data and Artificial Intelligence: The Story Behind the Outstanding Leadersh...
Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO - EURA...
Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO EURACTIV
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M - Fierce Biotech
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M Fierce Biotech
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters.com
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial Reuters.com
Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Q...
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan - Sleep Review
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan Sleep Review
Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego - Genetic Engineering & Biotechnology News
Shionogi, Qpex to Open Antimicrobial R&D Lab in San Diego Genetic Engineering & Biotechnology News
Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter - The Pharma Letter
Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter The Pharma Letter
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout - BioCentury
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout BioCentury
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Addre...
The past three years for Shionogi (TSE:4507) investors has not been profitable - Simply Wall St
The past three years for Shionogi (TSE:4507) investors has not been profitable Simply Wall St
Shionogi's antiviral comes up short in global COVID-19 trial - FiercePharma
Shionogi's antiviral comes up short in global COVID-19 trial FiercePharma
Recognized with the Double A List for Leadership in Corporate Transparency and Performance on Cli...
After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug - STAT
After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug STAT
Shionogi Acquires Full Ownership of Joint Ventures - TipRanks
Shionogi’s ensitrelvir prevents symptomatic COVID-19 - The Pharma Letter
Shionogi’s ensitrelvir prevents symptomatic COVID-19 The Pharma Letter
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment - The Hearing Review
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment The Hearing Review
Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study - FirstWord Pharma
Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study FirstWord Pharma
Maze lands new partner for Pompe drug, after Sanofi pact came apart - BioPharma Dive
Maze lands new partner for Pompe drug, after Sanofi pact came apart BioPharma Dive
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment - Precedence Research
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment Precedence Research
Shionogi Second Quarter 2025 Earnings: Revenues Beat Expectations - Simply Wall St
Shionogi Second Quarter 2025 Earnings: Revenues Beat Expectations Simply Wall St
Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next - Si...
Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next Simply Wall St
Insomnia drug launched by Nxera Pharma and Shionogi & Co - Cambridge Independent
Insomnia drug launched by Nxera Pharma and Shionogi & Co Cambridge Independent
Fenwick Represents Maze Therapeutics in Exclusive Worldwide License Agreement with Shionogi - Fen...
Fenwick Represents Maze Therapeutics in Exclusive Worldwide License Agreement with Shionogi Fenwick & West LLP
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Yahoo News Canada
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission Yahoo News Canada
Shionogi’s COVID-19 drug misses endpoint in global phase III - BioWorld Online
Shionogi’s COVID-19 drug misses endpoint in global phase III BioWorld Online
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models - BioWorld Online
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models BioWorld Online
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in ...
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open Business Wire
Shionogi reports data from Phase III portion of Covid-19 drug trial - Clinical Trials Arena
Shionogi reports data from Phase III portion of Covid-19 drug trial Clinical Trials Arena
Dialogue 2021｜シオノギ製薬（塩野義製薬） - Shionogi
Dialogue 2021｜シオノギ製薬（塩野義製薬） Shionogi
Keiko Tone - Shionogi - Board Member - The Association of the British Pharmaceutical Industry
Keiko Tone - Shionogi - Board Member The Association of the British Pharmaceutical Industry
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill - Nikkei Asia
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill Nikkei Asia
Japan's Shionogi seeks China approval for superbug-fighting antibiotic - Nikkei Asia
Japan's Shionogi seeks China approval for superbug-fighting antibiotic Nikkei Asia
SHIONOGI Infectious Disease Weeks - Shionogi
SHIONOGI Infectious Disease Weeks Shionogi
Masahiro Fujita - Shionogi
Masahiro Fujita Shionogi
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 National Institutes of Health
Shimadzu, Shionogi unveil international wastewater-based epidemiology lab at University of Tokyo,...
Shionogi’s oral COVID-19 antiviral wins full approval in Japan - BioWorld Online
Shionogi’s oral COVID-19 antiviral wins full approval in Japan BioWorld Online
Shionogi takes Akili’s ADHD digital therapy to Japan - pharmaphorum
Shionogi takes Akili’s ADHD digital therapy to Japan pharmaphorum
Digital Initiative for Non-Consumers 2024 - MM+M Awards - MM+M Online
Digital Initiative for Non-Consumers 2024 - MM+M Awards MM+M Online
Qpex Biopharma receives added BARDA funds for antibiotic development - University of Minnesota Tw...
Qpex Biopharma receives added BARDA funds for antibiotic development University of Minnesota Twin Cities
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's lat...
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest move The Business Journals
Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Mat...
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss - BSA bureau
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss BSA bureau
Taiwan approves Japan-based Shionogi's influenza drug for paediatric use - BSA bureau
Taiwan approves Japan-based Shionogi's influenza drug for paediatric use BSA bureau
Address the problem of antimicrobial resistance (AMR) - Shionogi
Address the problem of antimicrobial resistance (AMR) Shionogi
Mother to Mother SHIONOGI Project - Shionogi
Mother to Mother SHIONOGI Project Shionogi
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression - BioWorld Online
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression BioWorld Online
When Will We Get New COVID-19 Drugs? - TIME
Advancing Malaria Research: Nagasaki University and Shionogi Extend Industry-Academia Partnership...
Advancing Malaria Research: Nagasaki University and Shionogi Extend Industry-Academia Partnership nagasaki-u.ac.jp
History - Shionogi
History Shionogi
Margaret Borys - Shionogi
Margaret Borys Shionogi
Japan Aims to Cut Antibiotics Reliance on China by Resuming API Production - JAPAN Forward
Japan Aims to Cut Antibiotics Reliance on China by Resuming API Production JAPAN Forward
Nathan McCutcheon - Shionogi
Nathan McCutcheon Shionogi
What we stand for: Takeki Uehara | Clinical Development Vision and Strategy | Shionogi & Co., Ltd...
What we stand for: Takeki Uehara | Clinical Development Vision and Strategy | Shionogi & Co., Ltd. Shionogi
Obesity Clinical Trial Pipeline Appears Robust With 80+ Key - GlobeNewswire
Obesity Clinical Trial Pipeline Appears Robust With 80+ Key GlobeNewswire
Medium-Term Business Plan STS2030 Revision（FY2023 – FY2030） | Business Strategy | Shionogi & Co...
Tadashi Hara - Shionogi
Tadashi Hara Shionogi
Message from Top Management - Shionogi
Message from Top Management Shionogi
Partnering to Bring Meaningful Science to Patients - Shionogi
Shionogi and Osaka University unveils a new joint research lab to review anti-COVID-19 drug - BSA...
Shionogi and Osaka University unveils a new joint research lab to review anti-COVID-19 drug BSA bureau
Financial Highlights - Shionogi
Financial Highlights Shionogi
Diversity and inclusion | Attractive work environment | Shionogi & Co., Ltd. - Shionogi
Diversity and inclusion | Attractive work environment | Shionogi & Co., Ltd. Shionogi
Japan’s Nagasaki University and Shionogi extend industry-academia partnership to eliminate malari...
Japan’s Nagasaki University and Shionogi extend industry-academia partnership to eliminate malaria BSA bureau
New Antivirals for Today's COVID-19: Ensitrelvir and Beyond - Infectious Disease Special Edition
New Antivirals for Today's COVID-19: Ensitrelvir and Beyond Infectious Disease Special Edition
Two major breakthroughs in Fragile X Syndrome treatments - Pharmaceutical Technology
Two major breakthroughs in Fragile X Syndrome treatments Pharmaceutical Technology
Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacteri...
Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries Clinton Health Access Initiative
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat - ...
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat Nature.com
Shionogi to acquire Qpex Biopharma for $140m - Pharmaceutical Technology
Shionogi to acquire Qpex Biopharma for $140m Pharmaceutical Technology
Maze gets new Pompe partner after FTC blocks Sanofi deal - pharmaphorum
Maze gets new Pompe partner after FTC blocks Sanofi deal pharmaphorum
Shionogi sinks in Tokyo trade after panel again delays COVID pill approval - Reuters.com
Shionogi sinks in Tokyo trade after panel again delays COVID pill approval Reuters.com
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval - Reuters.com
Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval Reuters.com
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline - BioSpace
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline BioSpace
Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug - Business Wire
Kaneka to Manufacture and Supply Intermediates for Shionogi COVID-19 Drug Business Wire
WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean spor...
WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean sport WADA
Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Hea...
Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Headquarters in Amsterdam Business Wire
Shionogi Announces Strategic Re-Organization of U.S. Executive Leadership - Business Wire
Shionogi Announces Strategic Re-Organization of U.S. Executive Leadership Business Wire
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine - Fierc...
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine Fierce Biotech
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex ...
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc. Business Wire
New data from Japan shows early resolution of common Covid-19 symptoms - BioPharma-Reporter.com
New data from Japan shows early resolution of common Covid-19 symptoms BioPharma-Reporter.com
Japan's Shionogi says continuing Vietnam COVID projects after partner scandals - Reuters.com
Japan's Shionogi says continuing Vietnam COVID projects after partner scandals Reuters.com